Skip to main content
. 2013 Jun 3;4(9):1322–1332. doi: 10.1021/cn400116z

Figure 3.

Figure 3

In vivo evaluation of MJN110 as a MAGL inhibitor. Competitive ABPP analysis in brain and liver isolated from mice treated with 0.25–5.0 mg·kg–1 MJN110 by oral (A) or intraperitoneal (B) administration. (C) Brain lipid levels from mice treated with indicated doses of MJN110 showing dose-dependent elevation of 2-AG, reduction of AA and no detectable changes in NAEs. Data are presented as means ± SEM (n = 3 mice per group). *p < 0.05; **p < 0.01; ***p < 0.001 for vehicle-treated versus MJN110-treated mice. (D) In vivo time-course analysis of MJN110-mediated MAGL inhibition following a single 1.0 mg·kg–1 (p.o.) dose.